KENDRA NESS: Open Payments
NPI 1962892216 · SAN ANTONIO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,531 in 83 payments from 16 companies in 2025. Trend: 2023 $1,662 · 2024 $1,347 · 2025 $1,531
Food & beverage: $1,446Education: $85
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 23 | $327 |
| Janssen Biotech, Inc. | 14 | $292 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 9 | $179 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $148 |
| Lilly USA, LLC | 4 | $86 |
| Ipsen Biopharmaceuticals, Inc | 4 | $74 |
| QOL Medical, LLC | 3 | $73 |
| Celltrion USA Inc. | 3 | $63 |
| GENZYME CORPORATION | 3 | $61 |
| PFIZER INC. | 4 | $58 |
Products named: TREMFYA, RINVOQ, XIFAXAN, MAVYRET, OMVOH, ENTYVIO, IQIRVO, Sucraid.
Industry payments across TX — which companies pay providers there.
